Datavant has announced a strategic partnership with Indegene to enhance patient recruitment for clinical trials, with a focus on rare disease and other complex studies. By embedding Datavant’s bespoke data enrichment capabilities into Indegene’s NEXT Patient Recruitment platform, the two companies are enabling faster trial enrollment, fewer screen failures and more efficient recruitment processes for biopharmaceutical organisations.

Speaking in this regard, Arnaub Chatterjee, President and GM—Life Sciences, Datavant, said, “Rare diseases have long been defined by the impossibility of finding enough patients fast enough to bring new therapies to market. Together with Indegene, we are demonstrating how data enrichment solves that challenge today–and lays the foundation for a new model of clinical research in which sponsors can accelerate recruitment across even the most complex and hard-to-reach populations.”

Patient recruitment is one of the biggest hurdles in clinical development, particularly in rare diseases where eligible populations are small and dispersed. Datavant operates the nation’s largest health data retrieval network, spanning over 80,000 hospitals and clinics and processing over 100 million patient records annually. Combined with Indegene’s suite of digitally powered solutions for clinical trial recruitment, the partnership streamlines the identification of suitable participants for studies based on specific health data criteria.

The partnership enables biopharma companies to reduce site-level screen failures, accelerate enrollment timelines, improve the screen-to-randomisation ratios and drive more informed decision-making.

Ram Yeleswarapu, SVP, Enterprise Clinical Solutions, Indegene, said, “We are doubling down on enhancing our capabilities to deliver digital-first recruitment solutions for clients to transform clinical trial execution. Our partnership with Datavant is a key step in this journey. By integrating secure, real-time access to consented patient medical records into our screening process, we are minimising one of the greatest challenges in clinical trials–screen failures at sites due to incomplete and ineffective pre-screening. This collaboration reinforces our positioning as the industry's premier digital-first recruitment partner, empowering sponsors and sites with data-driven approaches that deliver measurable outcomes.”